Cancer Therapy

Ribozyme and Geron enter agreement for manufacture of GRN163

Published in Cancer Weekly, September 24th, 2002

Ribozyme Pharmaceuticals, Inc., (RZYM) announced that it has entered an agreement with Geron Corp. (GERN) under which Ribozyme will manufacture GRN163, Geron's lead anticancer drug.

GRN163 acts by inhibiting telomerase, an enzyme that facilitates indefinite cell division, an important factor in the development of cancers. This new agreement follows the successful process development collaboration between Geron and RPI, previously announced in December of 2001 for the scale up and optimization of the manufacturing process.

Preclinical studies of GRN163 have demonstrated antitumor activity in animal models of glioblastoma, prostate cancer, lymphoma,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-09-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry